• U.S. Department of Energy’s National Reactor Innovation Center picks 12 developers on 13 new projects to take part in the Nuclear Energy Launch Pad initiative.
• Oklo plans to build on the rapid deployment of the Groves Isotope Test Reactor in Texas with Groves 2 Forge, an isotope production and processing pilot facility.
• Groves 2 Forge to initially focus on producing lutetium-177, an isotope used in targeted cancer treatments.
• Oklo plans to transition Groves 2 Forge from pilot operations to commercial-scale isotope production with the appropriate U.S. Nuclear Regulatory Commission licenses for commercial operation.

Oklo Inc. (NYSE:OKLO) ("Oklo" or "the Company"), an advanced nuclear technology company, today announced it would advance the Groves isotope production facility (Groves 2 Forge) as part of the U.S. Department of Energy’s (DOE’s) National Reactor Innovation Center (NRIC) Nuclear Energy Launch Pad initiative. Through the initiative, Oklo’s Groves 2 Forge will build on the demonstration experience from Oklo’s Groves Isotope Test Reactor while including capabilities to produce, process, and purify critical isotopes.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.